Price alert —
Sign in to get a one-time email the moment KVUE crosses your price. Free accounts included.
Sign in / create a free accountKenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
KVUE last traded at $19.02, up 0.2% on the day; that's in the upper part of its 52-week range ($16.64–$20.13). Right now it's trading close to its recent average, with no strong stretch in either direction.
The next scheduled earnings report (2026-08-06) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
above KC1 lower, +0.23 ATR from EMA21 — bullish engulfing
- · Bullish engulfing — body fully covers prior red bar
- · Stochastic bull cross in oversold
- · Aligned with weak uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
On the latest daily bar, momentum sits mid-range (RSI 54), the trend is quiet (ADX 24), and trading is light at 0.6× normal volume. On the business side, revenue is growing 4% year over year and the business keeps about 12 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $12.47 (fair range $12–$24); today's price sits 53% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Gross margin 59% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.58 (fragile)
- ⚠ Negative retained earnings
- ⚠ Receivables growing faster than revenue
Price implies ~10% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
KVUE is a $36.5 billion company, priced at 23× last year's earnings, and it moves more calmly than the market (beta 0.4).
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 0.32 / 0.26
- Surprise
- +23.0%
- Next report
- 2026-08-06
About
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and e…